Analysis of MS Patients Who Have Had Greater Than 60 Infusions of Natalizumab

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
The purpose of this study is to explore the safety and efficacy data in clinic patients who have been treated with Natalizumab for more than 60 continuous infusions.
Epistemonikos ID: 108b576616fdd149edf751aaed2fbe3746ba8924
First added on: May 09, 2024